Cost-effectiveness of bladder cancer screening

Yair Lotan, Robert S. Svatek

Research output: Contribution to journalArticle

Abstract

Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

Original languageEnglish (US)
Pages (from-to)627-632
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume7
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Early Detection of Cancer
Urinary Bladder Neoplasms
Cost-Benefit Analysis
Urine
Tumor Biomarkers
Survival
Population
Neoplasms

Keywords

  • Bladder cancer
  • Cost-effectiveness
  • Screening

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Cost-effectiveness of bladder cancer screening. / Lotan, Yair; Svatek, Robert S.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 7, No. 6, 12.2007, p. 627-632.

Research output: Contribution to journalArticle

@article{0264f0d70963409c9cedcd8e41e61b30,
title = "Cost-effectiveness of bladder cancer screening",
abstract = "Bladder cancer is the fourth most common cancer in men and 25{\%} of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.",
keywords = "Bladder cancer, Cost-effectiveness, Screening",
author = "Yair Lotan and Svatek, {Robert S.}",
year = "2007",
month = "12",
doi = "10.1586/14737167.7.6.627",
language = "English (US)",
volume = "7",
pages = "627--632",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of bladder cancer screening

AU - Lotan, Yair

AU - Svatek, Robert S.

PY - 2007/12

Y1 - 2007/12

N2 - Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

AB - Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

KW - Bladder cancer

KW - Cost-effectiveness

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=37549068534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549068534&partnerID=8YFLogxK

U2 - 10.1586/14737167.7.6.627

DO - 10.1586/14737167.7.6.627

M3 - Article

C2 - 20528324

AN - SCOPUS:37549068534

VL - 7

SP - 627

EP - 632

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -